DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Thiotepa (Thiotepa Intracavitary) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

THIOTEPA SUMMARY

THIOTEPA FOR INJECTION USP

Thiotepa for Injection USP is an ethylenimine-type compound. It is supplied as a non-pyrogenic, sterile Iyophilized powder for intravenous, intracavitary or intravesical administration, containing 15 mg of thiotepa. Thiotepa is a synthetic product with antitumor activity.

Thiotepa (thiotepa INTRACAVITARY) is indicated for the following:

Thiotepa has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors:

  1. Adenocarcinoma of the breast.
  2. Adenocarcinoma of the ovary.
  3. For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.
  4. For the treatment of superficial papillary carcinoma of the urinary bladder.

While now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease.


See all Thiotepa indications & dosage >>

THIOTEPA NEWS HIGHLIGHTS

Published Studies Related to Thiotepa (Thiotepa Intracavitary)

A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. [2008.05]

Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. [2008.04]

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. [2008.03]

Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients aged 50 years and over. [2008]

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. [2007.11.26]

more >>

Clinical Trials Related to Thiotepa (Thiotepa Intracavitary)

Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma [Completed]

Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors [Active, not recruiting]

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma [Completed]

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer [Active, not recruiting]

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors [Active, not recruiting]

more >>

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008